JP2017537140A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537140A5 JP2017537140A5 JP2017538469A JP2017538469A JP2017537140A5 JP 2017537140 A5 JP2017537140 A5 JP 2017537140A5 JP 2017538469 A JP2017538469 A JP 2017538469A JP 2017538469 A JP2017538469 A JP 2017538469A JP 2017537140 A5 JP2017537140 A5 JP 2017537140A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- alkyl
- hydrogen
- different
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 21
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 230000006907 apoptotic process Effects 0.000 claims 3
- 230000024245 cell differentiation Effects 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- VTQODUPVJJIRNL-UHFFFAOYSA-N COC(=O)C=CC1=CC=C(C=C1)C1=CC2=C(C=C1)N(C)CCC2(C)C Chemical compound COC(=O)C=CC1=CC=C(C=C1)C1=CC2=C(C=C1)N(C)CCC2(C)C VTQODUPVJJIRNL-UHFFFAOYSA-N 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 229940124443 chemopreventive agent Drugs 0.000 claims 2
- 239000012627 chemopreventive agent Substances 0.000 claims 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 230000018109 developmental process Effects 0.000 claims 2
- IOLNBCWVYOJDQM-UHFFFAOYSA-N methyl 6-(1,4,4-trimethyl-2,3-dihydroquinolin-6-yl)naphthalene-2-carboxylate Chemical compound COC(=O)C1=CC2=CC=C(C=C2C=C1)C1=CC2=C(C=C1)N(C)CCC2(C)C IOLNBCWVYOJDQM-UHFFFAOYSA-N 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 238000001069 Raman spectroscopy Methods 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 238000002059 diagnostic imaging Methods 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 210000004209 hair Anatomy 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 150000004492 retinoid derivatives Chemical class 0.000 claims 1
- 210000004927 skin cell Anatomy 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 210000000515 tooth Anatomy 0.000 claims 1
- 125000004950 trifluoroalkyl group Chemical group 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 210000003905 vulva Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1417957.6 | 2014-10-10 | ||
| GB201417957A GB201417957D0 (en) | 2014-10-10 | 2014-10-10 | Fluorescent synthetic retinoids |
| GB1419496.3 | 2014-10-31 | ||
| GB201419496A GB201419496D0 (en) | 2014-10-31 | 2014-10-31 | Fluorescent synthetic retinoids |
| PCT/GB2015/052956 WO2016055800A2 (en) | 2014-10-10 | 2015-10-09 | Fluorescent synthetic retinoids |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017537140A JP2017537140A (ja) | 2017-12-14 |
| JP2017537140A5 true JP2017537140A5 (cg-RX-API-DMAC7.html) | 2018-12-27 |
| JP7178781B2 JP7178781B2 (ja) | 2022-11-28 |
Family
ID=54697607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017538469A Active JP7178781B2 (ja) | 2014-10-10 | 2015-10-09 | 蛍光合成レチノイド |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10759762B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3204357B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7178781B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107250112B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2015329798C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2962150C (cg-RX-API-DMAC7.html) |
| DK (1) | DK3204357T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2909874T3 (cg-RX-API-DMAC7.html) |
| PL (1) | PL3204357T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3204357T (cg-RX-API-DMAC7.html) |
| SI (1) | SI3204357T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016055800A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107176945B (zh) * | 2016-03-11 | 2021-06-08 | 中国科学院上海有机化学研究所 | 一种视黄酸类化合物、其制备方法、中间体及应用 |
| SG11201900843WA (en) | 2016-08-09 | 2019-02-27 | Univ Durham | Synthetic retinoids (in cell modulation) |
| GB201910239D0 (en) * | 2019-07-17 | 2019-08-28 | Lightox Ltd | Fluorescent systems for biological imaging and uses thereof |
| WO2021127250A1 (en) * | 2019-12-19 | 2021-06-24 | Orphagen Pharmaceuticals, Inc. | Rar-alpha compounds for inflammatory disease and male contraception |
| CN112479998B (zh) * | 2020-11-16 | 2022-03-15 | 广州中医药大学(广州中医药研究院) | 一种二氢喹啉类荧光探针及其制备方法与应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH651034A5 (de) * | 1982-05-12 | 1985-08-30 | Hoffmann La Roche | Chroman-, thiochroman- oder 1,2,3,4-tetrahydrochinolinderivate und ihre verwendung als arzneimittel-wirkstoffe. |
| ATE38835T1 (de) | 1983-07-05 | 1988-12-15 | Pfizer | Karbonsaeure-derivate verwendbar bei der verhuetung der zersetzung von knorpeln. |
| US5264578A (en) | 1987-03-20 | 1993-11-23 | Allergan, Inc. | Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity |
| US4810804A (en) | 1987-03-26 | 1989-03-07 | Allergan, Inc. | Acetylenes disubstituted with a phenyl group and a heterobicyclic group having retinoid-like activity |
| US5023341A (en) | 1989-09-19 | 1991-06-11 | Allergan, Inc. | Compounds having a disubstituted acetylene moiety and retinoic acid-like biological activity |
| US4980369A (en) | 1989-09-19 | 1990-12-25 | Allergan, Inc. | Acetylenes disubstituted with a phenyl group and a 2-substituted chromanyl or thiochromanyl group having retinoid-like activity |
| US5324840A (en) * | 1992-06-11 | 1994-06-28 | Allergan, Inc. | Method of treatment with compounds having retinoid-like activity and reduced skin toxicity and lacking teratogenic effects |
| AU6225894A (en) | 1993-01-11 | 1994-08-15 | Ligand Pharmaceuticals, Inc. | Compounds having selectivity for retinoid x receptors |
| BR9610875A (pt) * | 1995-10-06 | 1999-07-13 | Ligand Pharm Inc | Modulares rxr seletivos - dimeros e processos para seu uso |
| WO1998007716A2 (en) * | 1996-08-23 | 1998-02-26 | The Board Of Regents For Oklahoma State University | Heteroarotinoids-anticancer agents with receptor specificity and tgase activity |
| WO2000059861A1 (en) | 1999-04-06 | 2000-10-12 | Bristol-Myers Squibb Company | Selective retinoic acid analogs |
| US6906057B1 (en) * | 1999-06-11 | 2005-06-14 | Allergan, Inc. | Methods for modulating FXR receptor activity |
| US6127382A (en) * | 1999-08-16 | 2000-10-03 | Allergan Sales, Inc. | Amines substituted with a tetrahydroquinolinyl group an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| EP1303987A1 (en) | 2000-07-13 | 2003-04-23 | Koninklijke Philips Electronics N.V. | Mpeg-4 encoder and output coded signal of such an encoder |
| WO2002018361A2 (en) | 2000-08-29 | 2002-03-07 | Allergan, Inc. | Compounds having activity as inhibitors of cytochrome p450rai |
| US6387951B1 (en) | 2000-08-29 | 2002-05-14 | Allergan Sales, Inc. | Compounds having activity as inhibitors of cytochrome P450RAI |
| WO2003016267A1 (en) * | 2001-08-17 | 2003-02-27 | Incyte San Diego Incorporated | Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia |
| WO2005017185A2 (en) * | 2003-07-16 | 2005-02-24 | Ligand Pharmceuticals Incorporated | HEPATOCYTE NUCLEAR FACTOR 4α MODULATOR COMPOUNDS |
| EP1696899A1 (en) * | 2003-12-17 | 2006-09-06 | Allergan, Inc. | Methods for treating retinoid responsive disorders using selective inhibitors of cyp26a and cyp26b |
| JP2006063064A (ja) * | 2004-07-27 | 2006-03-09 | Takeda Chem Ind Ltd | 受容体作動剤 |
| WO2007041112A2 (en) | 2005-09-30 | 2007-04-12 | Janssen Pharmaceutica N.V. | Dihydro-[1h]-quinolin-2-one derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes |
| US20100247679A1 (en) * | 2006-04-24 | 2010-09-30 | Alltech, Inc. | Methods and compositions for altering cell function |
| WO2008025965A2 (en) | 2006-08-29 | 2008-03-06 | Reinnervate Limited | Retinoid compounds and their use |
| US8070989B2 (en) * | 2007-08-09 | 2011-12-06 | Hallstar Innovations Corp. | Photostabilization of retinoids with alkoxycrylene compounds |
| US9512111B2 (en) * | 2010-11-08 | 2016-12-06 | Lycera Corporation | N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease |
| MX344701B (es) * | 2011-02-03 | 2017-01-03 | Lupin Ltd | Derivados de pirrol como moduladores de nachr alfa 7. |
| JP2014527083A (ja) | 2011-09-15 | 2014-10-09 | アリゾナ ボード オブ リージェンツ， ア ボディー コーポレイト オブ ザ ステート オブ アリゾナ， アクティング フォー アンド オン ビハーフ オブ アリゾナ ステート ユニバーシティー | 治療用化合物 |
| WO2014008214A1 (en) * | 2012-07-02 | 2014-01-09 | Biogen Idec Ma Inc. | Biaryl-containing compounds as inverse agonists of ror-gamma receptors |
-
2015
- 2015-10-09 EP EP15798539.1A patent/EP3204357B1/en active Active
- 2015-10-09 PT PT157985391T patent/PT3204357T/pt unknown
- 2015-10-09 JP JP2017538469A patent/JP7178781B2/ja active Active
- 2015-10-09 AU AU2015329798A patent/AU2015329798C1/en active Active
- 2015-10-09 PL PL15798539T patent/PL3204357T3/pl unknown
- 2015-10-09 SI SI201531818T patent/SI3204357T1/sl unknown
- 2015-10-09 ES ES15798539T patent/ES2909874T3/es active Active
- 2015-10-09 WO PCT/GB2015/052956 patent/WO2016055800A2/en not_active Ceased
- 2015-10-09 US US15/514,923 patent/US10759762B2/en active Active
- 2015-10-09 CN CN201580067667.6A patent/CN107250112B/zh active Active
- 2015-10-09 DK DK15798539.1T patent/DK3204357T3/da active
- 2015-10-09 CA CA2962150A patent/CA2962150C/en active Active
-
2019
- 2019-05-28 AU AU2019203709A patent/AU2019203709B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017537140A5 (cg-RX-API-DMAC7.html) | ||
| JP2004505105A5 (cg-RX-API-DMAC7.html) | ||
| JP2012526822A5 (cg-RX-API-DMAC7.html) | ||
| RU2009144142A (ru) | Лечение возрастной дегенерации желтого пятна с применением ингибиторов фактора d комплемента | |
| JP2015508103A5 (cg-RX-API-DMAC7.html) | ||
| JP6936335B2 (ja) | 腺様嚢胞がんの治療のためのベンゼンスルホンアミド誘導体の医薬組成物 | |
| JP2020529441A5 (cg-RX-API-DMAC7.html) | ||
| JP2018526407A5 (cg-RX-API-DMAC7.html) | ||
| JP7033317B2 (ja) | 白内障の予防剤、治療剤、およびこれらを製造するためのｈａｔ阻害剤の使用 | |
| JP2011520877A5 (cg-RX-API-DMAC7.html) | ||
| Boutureira et al. | Acute pulmonary edema after diazepam–ketamine in a dog | |
| ES2792850T3 (es) | Método para tratar la fibrosis pulmonar idiopática | |
| Ding et al. | Triangular-shaped homologous heterostructure as photocatalytic H 2 S scavenger and macrophage modulator for rheumatoid arthritis therapy | |
| Khabilov et al. | Features dental care for patients with type 2 type depending on disturbance of Kidney function | |
| JP2017533928A5 (cg-RX-API-DMAC7.html) | ||
| US11896609B2 (en) | Pharmaceutical composition for treating inflammatory diseases comprising germanium telluride nanosheets coated with polyvinylpyrrolidone | |
| Volker et al. | Diagnostic imaging in veterinary dental practice | |
| Arwade et al. | Oral Schwannoma—an unusual oral presentation: Case report and literature review | |
| RU2458054C1 (ru) | Производное 3-(2,2,2-триметилгидразиний) пропионата - никотинат 3-(2,2,2-триметилгидразиний) пропионат калия, обладающее противоишемической активностью | |
| Kruchinin | Psychological characteristics of patients with missing teeth at initial contact and after orthopedic treatment | |
| RU2457198C1 (ru) | Производное 3-(2,2,2-триметилгидразиний)пропионата - глицинат 3-(2,2,2-триметилгидразиний)пропионат калия, обладающее противоишемической активностью | |
| Alshahrani et al. | Postpubertal cherubism, report of sever inherited cases | |
| JPWO2022270621A5 (cg-RX-API-DMAC7.html) | ||
| ES2753191T3 (es) | Dronedarona para su uso en leishmaniasis, formulaciones y asociaciones para su uso en leishmaniasis | |
| Pleiman et al. | Vascular disruption effects of MPC-6827 |